Erasca IPOs on Nasdaq

19 7 月 2021

Erasca IPOs on Nasdaq

EDBI has been part of Erasca’s journey since our investment in 2020, and celebrates with the team as their IPO bolsters the company’s war chest and accelerates development of their comprehensive suite of drugs targeting the Ras/MAPK pathway, furthering their mission of erasing cancer.

Read Erasca’s press release here:

https://investors.erasca.com/news-releases/news-release-details/erasca-announces-closing-initial-public-offering-and-full

Related Posts

Could Singapore become the next global biotech hub?

EdgeQ Closes $75M Series-B Investment and Ramps to Customers’ Demand for Its Award-Winning 5G+AI Base Station-on-a-Chip for 5G Networks

Proxtera announces successful first close, of Series Seed round of funding with Ant Group, CerraCap Ventures, and EDBI

What to watch in the biomedical space over the next five years

E-Newsletters

The Upside – EDBI E-Newsletter 2022 Q4

Reports

Our Inaugural Sustainability Report 2021/2022

Join our community!

Subscribe to our quarterly e-Newsletter, The Upside to find out what’s shaping the future industries of Singapore and the region.

Investing in high-growth technologies that shape the future economic pillars of Singapore since 1991.

About EDBI

Team

Portfolio

News and Insights

Careers

Contact Us

© 2024 EDBI. All rights reserved.